SARS-CoV-2 seroprevalence in healthcare workers and risk factors

Weber, Stéphanie; Didelot, Alice; Agrinier, Nelly; Biroulet, Laurent Peyrin; Schvoerer, Évelyne; Jeulin, Hélène

doi:10.1016/j.idh.2022.05.002

Cited by 3 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The observed association of smoking with decreased seropositivity was strong, stable across timepoints and subgroups, persistent when adjusted for potential confounding factors, and underscored by a dose–response association. The observed association with odds ratios around 0.5 were similarly observed in previously published seroprevalence studies of different designs [ 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 ]. Altogether, this supports a genuine relationship between smoking and lower seropositivity.…”

Section: Discussionsupporting

confidence: 87%

“…SARS-CoV-2 antibodies measured in serum of population-based studies’ participants provide insights into the proportion of individuals who have experienced infection. SARS-CoV-2 infection-mediated seroprevalence has been reported to be increased for medical personnel and decreased for smokers in numerous studies [ 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 ], including two studies from Germany [ 11 , 12 ] as well as our baseline (BL) assessment of the Tirschenreuth Study (TiKoCo) [ 13 ]. With the exception of [ 12 ], these results were based on cross-sectional data collected shortly after the first pandemic wave (summer 2020) or in fall 2020.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Higher Infection Risk among Health Care Workers and Lower Risk among Smokers Persistent across SARS-CoV-2 Waves—Longitudinal Results from the Population-Based TiKoCo Seroprevalence Study

Guenther

Einhauser

Peterhoff

et al. 2022

IJERPH

View full text Add to dashboard Cite

SARS-CoV-2 seroprevalence was reported as substantially increased in medical personnel and decreased in smokers after the first wave in spring 2020, including in our population-based Tirschenreuth Study (TiKoCo). However, it is unclear whether these associations were limited to the early pandemic and whether the decrease in smokers was due to reduced infection or antibody response. We evaluated the association of occupation and smoking with period-specific seropositivity: for the first wave until July 2020 (baseline, BL), the low infection period in summer (follow-up 1, FU1, November 2020), and the second/third wave (FU2, April 2021). We measured binding antibodies directed to SARS-CoV-2 nucleoprotein (N), viral spike protein (S), and neutralizing antibodies at BL, FU1, and FU2. Previous infection, vaccination, smoking, and occupation were assessed by questionnaires. The 4181 participants (3513/3374 at FU1/FU2) included 6.5% medical personnel and 20.4% current smokers. At all three timepoints, new seropositivity was higher in medical personnel with ORs = 1.99 (95%-CI = 1.36–2.93), 1.41 (0.29–6.80), and 3.17 (1.92–5.24) at BL, FU1, and FU2, respectively, and nearly halved among current smokers with ORs = 0.47 (95%-CI = 0.33–0.66), 0.40 (0.09–1.81), and 0.56 (0.33–0.94). Current smokers compared to never-smokers had similar antibody levels after infection or vaccination and reduced odds of a positive SARS-CoV-2 result among tested. Our data suggest that decreased seroprevalence among smokers results from fewer infections rather than reduced antibody response. The persistently higher infection risk of medical staff across infection waves, despite improved means of protection over time, underscores the burden for health care personnel.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Introductionmentioning

confidence: 99%

Higher Infection Risk among Health Care Workers and Lower Risk among Smokers Persistent across SARS-CoV-2 Waves—Longitudinal Results from the Population-Based TiKoCo Seroprevalence Study

Guenther

Einhauser

Peterhoff

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…Además, otro estudio demostró que podrían interferir en alcanzar una inmunidad robusta a escala poblacional 17,23 . Se evidenció una frecuencia mayor de seropositivos en participantes con síntomas y dependiente del número de síntomas, resultados acordes a lo obtenido en diferentes trabajos ya publicados por otros autores, en los cuales se demostró que estas variables fueron estadísticamente asociadas a la seropositividad [24][25][26] . Así también, ya se ha reportado la asociación de síntomas específicos como ageusia, anosmia y disnea con la seropositividad en otros estudios realizados en países de Europa, en concordancia con nuestros resultados, donde observamos una frecuencia estadísticamente mayor de seropositivos en participantes con estos síntomas [27][28][29] .…”

Section: Discussionunclassified

Respuesta inmunitaria al SARS-CoV-2 previa a la vacunación en personal de salud de Alto Paraná, Paraguay, un estudio seroepidemiológico

Vargas Correa,

Segovia Coronel,

Bayer

et al. 2024

Rev. chil. infectol.

View full text Add to dashboard Cite

SARS-CoV-2 seroprevalence and associated factors of infection before and after the Delta wave in French Polynesia: a cross-sectional study

Mendiboure,

Teiti,

Aubry

et al. 2024

BMC Public Health

View full text Add to dashboard Cite

Background French Polynesia (FP) comprises 75 inhabited islands scattered across five archipelagos. Between July and October 2021, the SARS-CoV-2 Delta variant triggered a much stronger second epidemic wave in FP than the original Wuhan strain, which was dominant from August 2020 to March 2021. Although previous seroprevalence surveys made it possible to determine the proportion of the population infected by SARS-CoV-2 on the two most populated islands (Tahiti and Moorea) after the first (20.6% in Tahiti and 9.4% in Moorea) and second (57.7% in Tahiti) epidemic waves, no data are available for more remote islands. We used blood samples and personal data collected before, during, and after the second wave from inhabitants of several islands within the five archipelagos to assess the prevalence of SARS-CoV-2 infections and identify associated factors. Methods Blood samples and personal data were collected between April and December 2021 as part of the MATAEA study, a cross-sectional survey conducted on a random sample of the adult population representative of the five FP archipelagos and stratified by age and gender. IgG antibodies targeting the SARS-CoV-2 nucleocapsid (N) protein were detected using a recombinant antigen-based microsphere immunoassay. Factors associated with anti-SARS-CoV-2-N seropositivity were identified using logistic regression models. Results Of 1,120 participants, 503 (44.9%) tested positive for anti-SARS-CoV-2-N antibodies, corresponding to a weighted prevalence of 56.8% for the FP population aged 18–69 years. The seroprevalence increased from 21.9% to 62.1% before and during/after the Delta wave. Of these infections, only 28.4% had been diagnosed by health professionals. The odds of being seropositive were lower in males, participants recruited before the Delta wave, those who had never been married, those with a diagnosed respiratory allergy, smokers, and those vaccinated against COVID-19. Conclusions Our results confirm the high impact of the Delta wave in FP. By the end of 2021, 56.8% of the FP population aged 18–69 years had been infected by SARS-CoV-2; the majority of these infections went undetected. Individuals with respiratory allergies were found to be less susceptible to SARS-CoV-2 infection.

show abstract

SARS-CoV-2 seroprevalence in healthcare workers and risk factors

Cited by 3 publications

References 18 publications

Higher Infection Risk among Health Care Workers and Lower Risk among Smokers Persistent across SARS-CoV-2 Waves—Longitudinal Results from the Population-Based TiKoCo Seroprevalence Study

Higher Infection Risk among Health Care Workers and Lower Risk among Smokers Persistent across SARS-CoV-2 Waves—Longitudinal Results from the Population-Based TiKoCo Seroprevalence Study

Respuesta inmunitaria al SARS-CoV-2 previa a la vacunación en personal de salud de Alto Paraná, Paraguay, un estudio seroepidemiológico

SARS-CoV-2 seroprevalence and associated factors of infection before and after the Delta wave in French Polynesia: a cross-sectional study

Contact Info

Product

Resources

About